-

Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, 151 West 42nd Street, (4 Times Square), New York, NY 10036, on May 19, 2026.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, May 19, 2026, and Jeff Hawkins will participate in a fireside chat on the same day at 4:00 PM Eastern Time. A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to listen to the live webcast.

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Contacts

Investor and Media
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Quantum-Si Incorporated

NASDAQ:QSI

Release Summary
Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Release Versions

Contacts

Investor and Media
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

More News From Quantum-Si Incorporated

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™...

Quantum-Si Announces the Expansion of the Proteus™ Roadshow

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow...

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Back to Newsroom